Intramuscular triamcinolone in severe asthma

Sergio Salmeron, Olivier Sitbon, Philippe Herve, Gérald Simonneau, Pierre Duroux, René Caquet, S. Scott Nicholas, Joseph C. Kidney, R. W. Fuller, Peter J. Barnes, S. Capewell, D. T. McLeod, Raja G. Ogirala, Thomas K. Aldrich, David J. Prezant, M. Henry Williams

Research output: Contribution to journalLetterpeer-review


The article by Ogirala and colleagues (Feb. 28 issue)1 concerning high-dose intramuscular triamcinolone in severe, chronic, life-threatening asthma prompts the following comments. First, in our view the patients were probably undertreated on entry into the study: the maintenance dose of prednisone was 10 mg daily or less in half the patients (Patients 2, 6, 7, 9, 10, and 12), which is a low dose for patients at risk for fatal asthma.2 Moreover, the maintenance dose of inhaled corticosteroids (triamcinolone acetonide) is not mentioned. Second, the dose of prednisone used in the study (15 mg daily) is not …

Original languageEnglish (US)
Pages (from-to)429-431
Number of pages3
JournalNew England Journal of Medicine
Issue number6
StatePublished - Aug 8 1991

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Intramuscular triamcinolone in severe asthma'. Together they form a unique fingerprint.

Cite this